This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Alkermes plc (NASDAQ: ALKS) today will present an overview of its proprietary pipeline portfolio at its Research and Development (R&D) Day meeting for analysts and investors. For the first time, the company will discuss three new drug candidates including: a monomethyl fumarate (MMF) prodrug program for the treatment of multiple sclerosis; ALKS 7106 for the treatment of pain; and RDB 1419, a cancer immunotherapy candidate based on interleukin-2 (IL-2) and its receptors, Alkermes’ first proprietary biologic. These drug candidates demonstrate Alkermes’ focus on unmet medical needs in specific patient populations and show the productivity of the company’s expanded R&D capabilities.
In addition to the three newly unveiled drug candidates, the company will provide details on its later-stage pipeline candidates, specifically: commercial plans for aripiprazole lauroxil, a once-monthly, long-acting atypical antipsychotic currently in phase 3 development for the treatment of schizophrenia; review of the phase 2 data for ALKS 5461, a proprietary opioid modulator with a novel mechanism for the treatment of major depressive disorder (MDD); and the clinical rationale and development plan, including initiation of a phase 2 clinical study, for ALKS 3831, a proprietary oral compound designed as a broad spectrum antipsychotic treatment for schizophrenia.
“During this R&D Day, a more complete picture of our growth strategy will emerge,” commented Richard Pops, Chief Executive Officer of Alkermes. “Today we will be presenting a deeper look into our unique R&D engine that is powering one of the most diverse and exciting pipelines in the biotechnology industry, and bringing to light three innovative product candidates in important therapeutic fields. These new candidates are expected to follow our later-stage CNS product candidates: aripiprazole lauroxil for schizophrenia, ALKS 5461 for major depressive disorder and ALKS 3831 for schizophrenia, which represent growth opportunities over and above our five key commercial products.”
“The three new drug candidates that we are unveiling today exemplify the productivity of R&D at Alkermes – which now spans small molecules and biologics – and represent significant opportunities for us to address unmet needs for patients with major, chronic diseases: multiple sclerosis, pain and cancer,” stated Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. “Our distinctive approach is to build on a foundation of known pharmacology and clinical practice, then apply our R&D expertise and novel insights to create proprietary medicines with real value for patients and treatment systems. We will highlight for investors at our R&D Day how Alkermes employs a rigorous clinical development process that incorporates state-of-the-art clinical trial techniques and robust study designs so we can obtain data early in the development process to make rapid decisions about the most promising candidates in our pipeline.”